Metformin in Safety and Efficacy in Gouty Patients

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Nov 20, 2026 → Nov 20, 2027
See other at-risk trials from Mostafa Bahaa

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Nov 20, 2026 to Nov 20, 2027
    • Eligibility criteria expanded, about 6 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Mostafa Bahaa
14 trials monitored
See 1 trial at risk
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Trial Details
NCT Number NCT06924658
Lead Sponsor Mostafa Bahaa
Conditions
(from sponsor)		 Gout
Related terms Gout
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov